RBC Capital analyst Luca Issi reiterated an Outperform rating and $27.00 price target on WAVE Life Sciences (NASDAQ: WVE).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

WAVE Life Sciences (WVE) PT Lowered to $39 at Clear Street, 'we think ‘007 should find its optimal patient population'March 26, 2026 4:21 PM Form 4 Wave Life Sciences Ltd. For: Mar 23 Filed by: TAKANASHI KENMarch 26, 2026 4:17 PM WAVE Life Sciences (WVE) PT Lowered to $25 at Leerink PartnersMarch 26, 2026 2:47 PM TD Cowen on Arrowhead Pharma (ARWR): 'We remain at Buy as the pipeline remains robust'March 26, 2026 2:33 PM WAVE Life Sciences (WVE) PT Lowered to $18 at JefferiesMarch 26, 2026 2:01 PM WAVE Life Sciences (WVE) PT Lowered to $21 at BofA SecuritiesMarch 26, 2026 12:30 PM B.Riley on WAVE Life Sciences (WVE): 'a ~60% intraday selloff that, in our view, is significantly overdone'March 26, 2026 12:23 PM WAVE Life Sciences (WVE) PT Lowered to $12 at Raymond JamesMarch 26, 2026 11:31 AM Jefferies on WAVE Life Sciences (WVE): 'near-term pressure on stock'March 26, 2026 9:37 AM Leerink Partners on WAVE Life Sciences (WVE) after obesity data disappoints: selloff 'very overdone'March 26, 2026 9:00 AM Jones Trading on WAVE Life Sciences (WVE) GLP-1: 'we still see the chance for utility in elderly or patients with metabolic disease'March 26, 2026 8:55 AM Leerink on WAVE Life Sciences (WVE) Amid 52pct Collapse: 'The stock's reaction premarket... is very overdone in our opinion'March 26, 2026 8:52 AM Oppenheimer on WAVE Life Sciences (WVE): 'we would be buyers any weakness'March 26, 2026 8:20 AM Form 8-K Wave Life Sciences Ltd. For: Mar 26March 26, 2026 7:41 AM Wave Life Sciences reports phase 1 obesity drug resultsMarch 26, 2026 7:30 AM Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at SixMarch 26, 2026 7:30 AM